Lorber A, Kunishima D H, Harralson A F, Simon T M
J Rheumatol. 1983 Aug;10(4):568-73.
Unbound serum gold (UBSG) has received little attention, possibly because of rapid in vivo decay and in vivo concentration below the range of existing analytical procedures. We have recently developed a methodology enabling quantitation and study of UBSG during chrysotherapy to assess effects on cellular functions. UBSG after gold administration is labile, declining rapidly after attaining peak values at which lymphocyte mitogen response and polymorphonuclear phagocytosis were observed to be suppressed. Oral gold, i.e., auranofin, 3 mg BID as compared to systemic chrysotherapy 50 mg/wk, resulted in a higher percentage of UBSG to total serum gold.
未结合血清金(UBSG)很少受到关注,可能是因为其在体内迅速衰减且体内浓度低于现有分析方法的检测范围。我们最近开发了一种方法,能够在金疗法期间对UBSG进行定量和研究,以评估其对细胞功能的影响。给予金后,UBSG不稳定,在达到峰值后迅速下降,此时观察到淋巴细胞有丝分裂原反应和多形核细胞吞噬作用受到抑制。口服金,即硫代苹果酸金钠,每日两次,每次3毫克,与全身金疗法每周50毫克相比,UBSG占总血清金的百分比更高。